CPC Scientific selects Rocklin for its manufacturing plant

Installation at Atherton Business Park

Rocklin, Calif. – CPC Scientific Inc., one of the world’s leading synthetic peptide companies that helps bring life-changing therapies and diagnostics to market, has chosen Rocklin, Calif., as the site for its new US-based manufacturing site. The company will initially bring up to 50 high-quality jobs in life sciences and manufacturing.

The 41,000 square foot facility in the Atherton Business Park will be used to manufacture clinical and commercial grade peptide products, increasing CPC Scientific’s manufacturing capacity and diversifying its supply chain. (WebMD: What are peptides?)

“CPC has helped many of our customers bring an innovative drug to market from concept, said Shawn Lee, PhD, CEO. “With the new Rocklin site, we believe we will be able to contribute even more, particularly to the North American market, by using our decades of expertise in peptide synthesis to help our customers save lives and improve health. human health around the world.

Peptide-based therapeutic candidates

Peptide-based therapeutic candidates have been the fastest growing area among all chemical synthesis NCEs (New Chemical Entities) for new drug development in recent years.

For more than two decades, CPC Scientific has been a trusted partner to customers around the world, including multinational pharmaceutical companies, biotechnology companies and academic institutions, providing one-stop, value-added development and manufacturing services. to support their clinical trials. .

Fully operational in 2023

“The science may be complicated, but it’s easy to understand how this leader in life sciences can help build this industrial hub in the region and attract more businesses and high-paying jobs,” said Rocklin Mayor Bill Halldin. “We enjoyed getting to know the management of CPC Scientific as they finalized their choice of Rocklin and look forward to their continued success in biotech and life sciences.”
The new Rocklin CGMP facility is expected to be online and fully operational by 2023.

With manufacturing operations in Hangzhou (CN) and Rocklin, CA (USA), these facilities will enable CPC Scientific to help meet the growing global demand for peptide-based therapies and diagnostics.

Calvin W. Soper